Skip to main content
. 2022 Apr 20;30(7):2491–2504. doi: 10.1016/j.ymthe.2022.04.007

Figure 1.

Figure 1

APOL1 ASO effectively lowers APOL1 level in NEFTA/G2APOL1 transgenic mice

(A) Experimental design: NEFTA-rtTA/TREG2APOL1-GFP (NEFTA/G2APOL1) mice were generated. Animals were injected with control ASO, APOL1 ASO1, and ASO2 weekly and placed on a doxycycline diet for 10 days. (B) Representative images of APOL1 in situ hybridization in kidneys of NEFTA/G2APOL1 mice treated with control ASO, APOL1 ASO1, and ASO2. Scale bars of upper panels, 20 μm; lower panels, 10 μm. (C) Relative APOL1 mRNA levels measured by qRT-PCR in whole kidney lysates, ∗∗p ≤ 0.01 versus control ASO-treated mice. (D) Protein levels of APOL1 in kidneys of NEFTA/G2APOL1 mice treated with control ASO, APOL1 ASO1, or ASO2. Each lane represents one mouse. GAPDH and actin were used as a loading control. (E) Quantification of relative APOL1 protein levels in groups from (D), ∗∗p ≤ 0.01 versus control ASO-treated mice.